Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Analysis of Neutralization Antibodies in Patients With Mild COVID-19 Infection After 100 Days Using Microneutralization Test

Full metadata record
DC Field Value Language
dc.contributor.author안민주-
dc.contributor.author정대균-
dc.contributor.author이규선-
dc.contributor.author이승준-
dc.contributor.author류병한-
dc.contributor.author양혜련-
dc.contributor.author김선주-
dc.date.accessioned2022-12-26T09:21:04Z-
dc.date.available2022-12-26T09:21:04Z-
dc.date.issued2022-03-
dc.identifier.issn2288-0585-
dc.identifier.issn2288-6850-
dc.identifier.urihttps://scholarworks.gnu.ac.kr/handle/sw.gnu/2475-
dc.description.abstractNeutralizing antibodies play a critical role in blocking viral infections and in viral clearanceduring acute infection. The microneutralization assay and enzyme-linked immunosorbentassay (ELISA) targeting the receptor binding domain were performed for 30 patients withmild coronavirus disease (COVID)-19 infections. The elapsed number of days between samplecollection and diagnosis was 115 days, and real-time polymerase chain reaction (PCR) cyclethreshold (Ct) values at diagnosis were recorded. Clinical characteristics and Ct values werecompared between neutralization antibody-positive and -negative patients as measured bythe microneutralization assay. Neutralization antibody-positive patients (n = 9) were likelyto be older, have low Ct values, have more pneumonia during admission, and have a higheroptical density in ELISA than the neutralization antibody-negative patients (n = 21). Elderlypeople seemed to have a higher viral load causing more pneumonia and to produce moreneutralization antibodies. Neutralization antibodies persisted in only 30% of patients asdetected by microneutralization test after 100 days of diagnosis.-
dc.format.extent5-
dc.language영어-
dc.language.isoENG-
dc.publisher대한임상미생물학회-
dc.titleAnalysis of Neutralization Antibodies in Patients With Mild COVID-19 Infection After 100 Days Using Microneutralization Test-
dc.title.alternativeCOVID-19 경증 감염 100일 이후 세포독성 효과를 이용한 중화항체 측정-
dc.typeArticle-
dc.publisher.location대한민국-
dc.identifier.doi10.5145/ACM.2022.25.1.4-
dc.identifier.bibliographicCitationAnnals of Clinical Microbiology, v.25, no.1, pp 29 - 33-
dc.citation.titleAnnals of Clinical Microbiology-
dc.citation.volume25-
dc.citation.number1-
dc.citation.startPage29-
dc.citation.endPage33-
dc.identifier.kciidART002821275-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClasskci-
dc.subject.keywordAuthorKeywords: Antibody-
dc.subject.keywordAuthorCOVID-19-
dc.subject.keywordAuthorNeutralization-
dc.subject.keywordAuthorSARS-CoV-2-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medicine > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Altmetrics

Total Views & Downloads

BROWSE